JP2014210824A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014210824A5 JP2014210824A5 JP2014168689A JP2014168689A JP2014210824A5 JP 2014210824 A5 JP2014210824 A5 JP 2014210824A5 JP 2014168689 A JP2014168689 A JP 2014168689A JP 2014168689 A JP2014168689 A JP 2014168689A JP 2014210824 A5 JP2014210824 A5 JP 2014210824A5
- Authority
- JP
- Japan
- Prior art keywords
- gastritis
- treatment
- prostaglandin
- prevention
- agonist component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000007882 Gastritis Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000003180 prostaglandins Chemical class 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 2
- 229940037467 helicobacter pylori Drugs 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Claims (4)
- ヘリコバクター・ピロリ(Helicobacter pylori)誘発性胃炎、萎縮性胃炎、悪性貧血、術後アルカリ性胃炎および好酸球性胃腸炎からなる群から選ばれる哺乳類の疾患または症状の治療または予防用薬剤を製造するための、下記の構造を有するプロスタグランジンEP4アゴニスト成分の使用。
- 前記哺乳類が、前記症状または疾患に対して予防的治療を必要とする、請求項１記載の使用。
- 前記疾患または症状の治療または予防が、前記プロスタグランジンEP4アゴニスト成分を前記哺乳類の胃腸管に投与することを含む、請求項１または２記載の使用。
- 下記の構造を有するプロスタグランジンEP4アゴニスト成分を含む、ヘリコバクター・ピロリ(Helicobacter pylori)誘発性胃炎、萎縮性胃炎、悪性貧血、術後アルカリ性胃炎および好酸球性胃腸炎からなる群から選ばれる哺乳類の疾患または症状の治療または予防用の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87044406P | 2006-12-18 | 2006-12-18 | |
| US60/870,444 | 2006-12-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543060A Division JP2010513551A (ja) | 2006-12-18 | 2007-12-11 | 胃腸疾患の治療方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014210824A JP2014210824A (ja) | 2014-11-13 |
| JP2014210824A5 true JP2014210824A5 (ja) | 2014-12-25 |
Family
ID=39059771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543060A Ceased JP2010513551A (ja) | 2006-12-18 | 2007-12-11 | 胃腸疾患の治療方法および組成物 |
| JP2014168689A Ceased JP2014210824A (ja) | 2006-12-18 | 2014-08-21 | 胃腸疾患の治療方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543060A Ceased JP2010513551A (ja) | 2006-12-18 | 2007-12-11 | 胃腸疾患の治療方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100081631A1 (ja) |
| EP (3) | EP2548559A1 (ja) |
| JP (2) | JP2010513551A (ja) |
| AU (1) | AU2007334038A1 (ja) |
| BR (1) | BRPI0721067A2 (ja) |
| CA (1) | CA2690273A1 (ja) |
| WO (1) | WO2008076703A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855226B2 (en) * | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
| KR20150050595A (ko) | 2006-03-28 | 2015-05-08 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
| US20090012165A1 (en) * | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
| AU2011282549A1 (en) * | 2010-07-30 | 2013-02-28 | Allergan, Inc. | Compounds and methods for skin repair |
| US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| RU2586040C1 (ru) * | 2014-12-25 | 2016-06-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства Здравоохранения Российской Федерации (ГБОУ ВПО НижГМА Минздрава России) | Способ диагностики идиопатической язвенной болезни желудка и двенадцатиперстной кишки |
| CN107849072B (zh) | 2015-06-12 | 2020-12-15 | 西蒙弗雷泽大学 | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 |
| NL2018407B1 (en) * | 2017-02-22 | 2018-09-17 | Skytree B V | Improved process and apparatus for the removal of metabolic carbon dioxide from a confined space |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| US6586468B1 (en) | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
| CN1476429A (zh) * | 2000-11-27 | 2004-02-18 | �Ʒ� | 治疗骨质疏松的ep4受体选择性激动剂 |
| WO2003074483A1 (fr) * | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
| US7855226B2 (en) * | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
| CA2585367A1 (en) * | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
-
2007
- 2007-12-11 CA CA2690273A patent/CA2690273A1/en not_active Abandoned
- 2007-12-11 EP EP12188643A patent/EP2548559A1/en not_active Withdrawn
- 2007-12-11 BR BRPI0721067-1A patent/BRPI0721067A2/pt not_active IP Right Cessation
- 2007-12-11 WO PCT/US2007/087042 patent/WO2008076703A1/en active Application Filing
- 2007-12-11 EP EP07855057A patent/EP2120962A1/en not_active Ceased
- 2007-12-11 JP JP2009543060A patent/JP2010513551A/ja not_active Ceased
- 2007-12-11 US US12/519,215 patent/US20100081631A1/en not_active Abandoned
- 2007-12-11 EP EP12159850A patent/EP2465506A1/en not_active Withdrawn
- 2007-12-11 AU AU2007334038A patent/AU2007334038A1/en not_active Abandoned
-
2014
- 2014-08-21 JP JP2014168689A patent/JP2014210824A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014210824A5 (ja) | ||
| NZ624922A (en) | Orally administered corticosteroid compositions | |
| EA201690962A1 (ru) | Составы | |
| DOP2017000294A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| RU2019131148A (ru) | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы | |
| JP2013014622A5 (ja) | ||
| CY1117118T1 (el) | Φαρμακευτικος συνδυασμος για την αγωγη του πονου | |
| JP2013525444A5 (ja) | ||
| JP2013032389A5 (ja) | ||
| JP2015110588A5 (ja) | ||
| MX2018003975A (es) | Combinacion de glicosaminoglicanos y un agente antacido y sus composiciones. | |
| JP2014221827A5 (ja) | ||
| JP2014507477A5 (ja) | ||
| EA201001781A1 (ru) | Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов | |
| SA517390550B1 (ar) | وحدة جرعة قابلة للتفتت في الفم تتضمن مكون أستيترول | |
| JP2011527299A5 (ja) | ||
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| JP2009505991A5 (ja) | ||
| BR112015019264A2 (pt) | composições farmacêuticas para o tratamento de helicobacter pylori | |
| JP2012528856A5 (ja) | ||
| JP2017505809A5 (ja) | ||
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| JP2008539169A5 (ja) | ||
| WO2021074649A3 (en) | Methods of promoting scfa production by gut microbiota |